Harnaaz Sandhu's Dramatic Weight Loss: The Secret Exercise Behind Her Transformation

Harnaaz Sandhu, Miss Universe 2021, has undergone a dramatic weight loss transformation for her Bollywood debut in Baaghi 4. The beauty queen has revealed that she silently battled celiac disease, an autoimmune condition causing weight gain and nutritional deficiencies. She has adopted a strict gluten-free diet and incorporated Pilates into her daily routine, leading to a noticeable transformation in her physique. Despite trolls and criticism, Harnaaz is determined to take back control and has inspired fans with her strength and comeback.

Teva Pharmaceuticals has recently made a significant stride in the pharmaceutical industry with the FDA approval and U.S. launch of its first generic version of Saxenda® (liraglutide injection), a glucagon-like peptide 1 (GLP-1) receptor agonist indicated for weight loss [2]. This launch is part of Teva's broader strategy to expand its complex generic medicine portfolio, aligning with its Pivot to Growth Strategy.

Saxenda®, originally developed by Novo Nordisk, has been a prominent player in the weight loss market, with annual sales of $165 million as of June 2025 [2]. The generic version of Saxenda® is expected to capitalize on the growing demand for GLP-1 therapies in the U.S. market, offering patients a more affordable option.

Liraglutide injection, the active ingredient in Saxenda®, works by combining with a reduced-calorie diet and increased physical activity to reduce body weight. It is indicated for adults with obesity or overweight (excess weight) who also have weight-related medical problems, and pediatric patients (12-17 years) with a weight greater than 60 kg and obesity to help them lose weight and keep the weight off [2].

However, the launch of the generic version of Saxenda® comes with potential concerns. The drug carries significant safety information, including potential thyroid tumors and pancreatitis risks, which may deter patients and healthcare providers from its usage [2]. Additionally, the reliance on generic products may expose Teva to increased competition and price pressures in the market, raising concerns about the sustainability of its business model.

Investor sentiment towards Teva Pharmaceuticals has been mixed. While the stock has seen insider trading activity, with 21 insiders selling shares in the past six months, hedge funds have shown increased interest in the stock, with 250 institutional investors adding shares to their portfolio in the most recent quarter [2]. Wall Street analysts have issued mostly positive ratings, with five firms issuing buy ratings and no firms issuing sell ratings [2].

The success of Teva's generic Saxenda® launch will depend on its ability to navigate potential side effects and market competition. The launch marks a significant milestone in Teva's generics portfolio, showcasing its commitment to innovation and addressing patient needs in the growing weight loss market.

References:
[1] https://www.aajtak.in/visualstories/entertainment/harnaaz-sandhu-weight-loss-transformation-photos-viral-tmovk-257507-27-08-2025
[2] https://www.quiverquant.com/news/Teva+Pharmaceuticals+Announces+FDA+Approval+and+Launch+of+First+Generic+GLP-1+for+Weight+Loss%2C+Saxenda%C2%AE+%28Liraglutide+Injection%29